Icosapent Ethyl

Diabetes, Cardiovascular Events, Diet + 4 more

Treatment

8 FDA approvals

20 Active Studies for Icosapent Ethyl

What is Icosapent Ethyl

Icosapent ethyl

The Generic name of this drug

Treatment Summary

Icosapent ethyl is a synthetic form of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an additional treatment for very high levels of triglycerides (TG) in the blood (greater than 500 milligrams per deciliter). The FDA approved it in 2012.

Vascepa

is the brand name

image of different drug pills on a surface

Icosapent Ethyl Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vascepa

Icosapent ethyl

2012

14

Approved as Treatment by the FDA

Icosapent ethyl, otherwise known as Vascepa, is approved by the FDA for 8 uses such as Diabetes Mellitus and elevation of serum triglyceride levels .

Diabetes Mellitus

elevation of serum triglyceride levels

Diabetes

Cardiovascular Events

Hospitalizations

Cardiovascular Disease

Hypertriglyceridemia

Cardiovascular Diseases

Effectiveness

How Icosapent Ethyl works in the body

EPA helps to reduce triglyceride levels by increasing fat burning, stopping fat production in the liver, and boosting the activity of a protein that helps break down triglycerides. These effects work together to help lower the amount of triglycerides in the body.

When to interrupt dosage

The allotment of Icosapent Ethyl is contingent upon the diagnosed condition. The dose likewise depends on the technique of administration specified in the table below.

Condition

Dosage

Administration

Diabetes

, 1000.0 mg, 500.0 mg, 0.625 mg, 998.0 mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Cardiovascular Events

, 1000.0 mg, 500.0 mg, 0.625 mg, 998.0 mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Cardiovascular Disease

, 1000.0 mg, 500.0 mg, 0.625 mg, 998.0 mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Hypertriglyceridemia

, 1000.0 mg, 500.0 mg, 0.625 mg, 998.0 mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Cardiovascular Diseases

, 1000.0 mg, 500.0 mg, 0.625 mg, 998.0 mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Diet

, 1000.0 mg, 500.0 mg, 0.625 mg, 998.0 mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Hospitalizations

, 1000.0 mg, 500.0 mg, 0.625 mg, 998.0 mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

Icosapent Ethyl has one contraindication, thus it should not be employed for any of the ailments listed in the subsequent table.

Icosapent Ethyl Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Icosapent Ethyl may interact with Pulse Frequency

There are 20 known major drug interactions with Icosapent Ethyl.

Common Icosapent Ethyl Drug Interactions

Drug Name

Risk Level

Description

Abrocitinib

Major

The risk or severity of bleeding and thrombocytopenia can be increased when Icosapent ethyl is combined with Abrocitinib.

Aldesleukin

Minor

The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Aldesleukin.

Alemtuzumab

Minor

The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alemtuzumab.

Altretamine

Minor

The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Altretamine.

Amsacrine

Minor

The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Amsacrine.

Icosapent Ethyl Toxicity & Overdose Risk

Icosapent ethyl is generally safe and any reported side effects are not related to taking the drug.

image of a doctor in a lab doing drug, clinical research

Icosapent Ethyl Novel Uses: Which Conditions Have a Clinical Trial Featuring Icosapent Ethyl?

Four investigations are currently analyzing the potential of Icosapent Ethyl to mitigate Hypertriglyceridemia.

Condition

Clinical Trials

Trial Phases

Diabetes

74 Actively Recruiting

Phase 1, Not Applicable, Phase 4, Phase 2, Phase 3

Hospitalizations

1 Actively Recruiting

Not Applicable

Cardiovascular Events

4 Actively Recruiting

Not Applicable

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Hypertriglyceridemia

0 Actively Recruiting

Cardiovascular Diseases

0 Actively Recruiting

Cardiovascular Disease

27 Actively Recruiting

Not Applicable, Early Phase 1, Phase 3, Phase 2

Icosapent Ethyl Reviews: What are patients saying about Icosapent Ethyl?

5

Patient Review

7/13/2018

Icosapent Ethyl for High Amount of Triglyceride in the Blood

I'm really pleased with this medication. I saw a significant reduction in my triglyceride levels within six months of taking two capsules twice daily.

4.3

Patient Review

2/27/2017

Icosapent Ethyl for High Amount of Triglyceride in the Blood

I take two 1gm capsules twice daily during meals and it lowered my triglyceride levels by 1/3 . Only side effect was wrist joint pain that eventually went away. Highly recommend it, even though it can be quite expensive without insurance.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about icosapent ethyl

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is icosapent ethyl the same as fish oil?

"Vascepa (icosapent ethyl) is a prescription omega-3 fatty acid. It is similar to fish oil, but not exactly the same."

Answered by AI

What is icosapent ethyl prescribed for?

"Icosapent ethyl is a drug used to control high triglyceride levels in the blood when taken with a proper diet."

Answered by AI

Is icosapent ethyl good for you?

"When taken together with a statin, Vascepa (icosapent ethyl) can help protect the heart of certain people who are at high risk of heart disease by lowering their triglyceride levels."

Answered by AI

What is the difference between Vascepa and icosapent ethyl?

"Omega-3-acid ethyl esters, also known by its brand name Lovaza, is a medication taken in the form of a capsule that is swallowed. It is taken either once or twice a day. Another medication, Vascepa, which is also a formulation of omega-3 fatty acids derived from fish oil, is taken in the same way, but twice a day."

Answered by AI

Clinical Trials for Icosapent Ethyl

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of University of Alberta in Edmonton, Canada.

Pharmacist-led Care for Diabetes

18+
All Sexes
Edmonton, Canada

As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, but need to give people more support to help them manage their diabetes. Pharmacists are respected health care professionals who are often easier to see that doctors and can help people with diabetes to stay as healthy as possible. This research project aims to see whether a pharmacist service can help improve diabetes management in people with type 2 diabetes compared to usual care from their family physician or nurse practitionner. The potential impact of this project is to empower people with type 2 diabetes to understand their condition, it's management, and to achieve target blood sugar levels, which will ultimately reduce the risk of diabetes-related complications.

Recruiting
Has No Placebo

University of Alberta

Ross Tsuyuki, BScPharm, PharmD, MSc

Image of Brigham and Women's Hospital in Boston, United States.

Rosuvastatin for Cancer-Associated Blood Clots

18+
All Sexes
Boston, MA

Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.

Phase 4
Waitlist Available

Brigham and Women's Hospital (+1 Sites)

Have you considered Icosapent Ethyl clinical trials?

We made a collection of clinical trials featuring Icosapent Ethyl, we think they might fit your search criteria.
Go to Trials
Image of University of Toronto in Toronto, Canada.

Time Restricted Eating for Breast Cancer Survivors

60 - 85
Female
Toronto, Canada

After chemotherapy, older breast cancer survivors experience a faster decline in brain function. This can make it harder to enjoy life, stay social, and maintain independence. Chemotherapy can lead to poorer lifestyle habits, like unhealthy eating, less exercise, high stress, and poor sleep. Chemotherapy can also affect important health markers like blood sugar and cholesterol. Over time, these changes can damage blood vessels, which might lead to heart and brain issues. The investigators do not fully understand why brain function declines faster after chemotherapy, especially in older survivors, because there are many factors involved. In this study, the investigators will look at how lifestyle habits (like diet, exercise, stress and sleep), health markers (like blood sugar and cholesterol), and blood vessel health (like how well blood flows and how stiff the blood vessels are) affect brain function in older breast cancer survivors. The investigators will include 152 females aged 60-85 years, who finished chemotherapy for early-stage breast cancer at least 1 year ago. The investigators will use special tests to check different parts of brain function, like language, memory, and attention, as well as brain blood vessel health. This will help to understand which factors might speed up or slow down memory and thinking problems. Since many Canadian breast cancer survivors experience faster decline in brain function after chemotherapy, this study aims to find out what might make it worse. The results could help to create better and more personalized treatment plans for older breast cancer survivors that protect brain health and reduce problems with brain function in the future.

Waitlist Available
Has No Placebo

University of Toronto

Amy A Kirkham, PhD

Have you considered Icosapent Ethyl clinical trials?

We made a collection of clinical trials featuring Icosapent Ethyl, we think they might fit your search criteria.
Go to Trials
Image of Duke Center for Living in Durham, United States.

Exendin-9 + Dexamethasone for Insulin Resistance

18 - 60
All Sexes
Durham, NC

Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects. This protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.

Phase 1
Recruiting

Duke Center for Living

David D'Alessio, MD

Image of Baltimore VA Medical Center in Baltimore, United States.

Continuous Glucose Monitors for Diabetes

18 - 90
All Sexes
Baltimore, MD

Among the diffident groups of patients, those with chronic and severe medical conditions are more likely to be readmitted to the hospital. It is not surprising therefore that patients with diabetes have high readmission rates. Patients with diabetes have 40% higher re-hospitalization rates compared with those patients without diabetes, with 30-day readmission rates reported to range between 14% and 26%. It should be noted that almost 30% of the patients with diabetes are experiencing two or more hospital admissions per year, accounting for more than 50% of total hospitalizations and hospital health care costs. This research application will evaluate whether the initiation of Continuous Glucose Monitor (CGM) devices at the time of hospital discharge will lead to better glucose control and health outcomes compared to the use of "finger sticks" Point of Care (POC) following hospital discharge among patients with diabetes. This study will be a two arm (Real Time CGM vs POC) single center RCT at the Baltimore VA Medical Center. One hundred and twenty individuals will be recruited and randomly assigned (1:1) to either Real Time CGM or to POC following hospital discharge. All subjects will be followed from for 3 months post hospital discharge.

Waitlist Available
Has No Placebo

Baltimore VA Medical Center

Ilias Spanakis, MD

DexCom, Inc.

Have you considered Icosapent Ethyl clinical trials?

We made a collection of clinical trials featuring Icosapent Ethyl, we think they might fit your search criteria.
Go to Trials